EUVIMEDEUVIMED entdecken
Crossref

Reversal of the Marketing Authorizations for HPV Vaccines and Uncertainty Regarding Utilization in China

Na Li, Xiang Yu

Biotechnology Law Report · 2018-08 · 37 (4) · 211-214

DOI: 10.1089/blr.2018.29081.nl ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Law Report, 2018-08. Verfasst von Na Li und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 1 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

, by April 2018, the China Food and Drug Administration (CFDA) had quickly approved the marketing authorizations of a 9-valent HPV vaccine. This reversal in how long HPV vaccine approval in China took is gratifying, but there remain some issues and uncertainties in the use of the vaccines, which continue to negatively impact Chinese women’s health.

Zitieren

APA

Li, N., & Yu, X. (2018). Reversal of the Marketing Authorizations for HPV Vaccines and Uncertainty Regarding Utilization in China. Biotechnology Law Report, 37(4), 211-214. https://doi.org/10.1089/blr.2018.29081.nl

Vancouver

Li N, Yu X. Reversal of the Marketing Authorizations for HPV Vaccines and Uncertainty Regarding Utilization in China. Biotechnology Law Report. 2018;37(4):211-214. doi:10.1089/blr.2018.29081.nl

BibTeX
@article{Li2018,
  author = {Li, Na and Yu, Xiang},
  title = {Reversal of the Marketing Authorizations for HPV Vaccines and Uncertainty Regarding Utilization in China},
  journal = {Biotechnology Law Report},
  year = {2018},
  volume = {37},
  number = {4},
  pages = {211--214},
  doi = {10.1089/blr.2018.29081.nl}
}
Kostenlos starten →